Sleep Disorders, Circadian Rhythm Clinical Trial
Official title:
A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)
Verified date | May 22, 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will examine the effect of bright light or melatonin treatment on sleep in
children with Smith-Magenis syndrome (SMS), a genetic disorder characterized by certain
physical, behavioral and developmental features. Patients have a disrupted sleep cycle
involving early waking, frequent daytime napping and frequent nighttime awakenings. Melatonin
is a hormone normally produced at night in healthy people. People with SMS produce high
levels of melatonin during the daytime and very low levels at night. This may affect their
behavior, mood, attention span and sleep patterns.
Healthy volunteers between 18 and 45 years of age and children with SMS who are between 3 and
16 years of age may be eligible for this study.
Healthy subjects are admitted to the NIH Clinical Center overnight. In the morning they take
one dose of time-release melatonin and have blood and saliva samples collected hourly from
7:00 AM to 6:00 PM.
Children with SMS participate in a 2-part study, as follows:
Part 1 Inpatient Trial
Pre-trial at-home phase: During the month before NIH inpatient admission, participants do the
following:
- Wear an actiwatch device or keep a daily sleep diary to monitor daytime alertness, mood
shifts and sleep patterns.
- Complete a behavior assessment survey related to the child s behaviors and sleep
patterns.
- Obtain frequent body temperature measurements.
- Collect several saliva samples over a 24-hour period.
NIH admission phase:
- Children are admitted to the NIH Clinical Center for 2-3 nights for bright light
treatment. They remain in their rooms for alternating periods of exposure to standard
dim room light and bright light, using a light box placed within 3 to 5 feet of the
child. An electroencephalogram (EEG) with additional electrodes to track eye movements
is used to monitor the child s attention. Between 8AM and 6PM serial blood samples are
collected to measure melatonin levels. A parent rates the child s mood and behavior
during the 2-day test period.
- Children are admitted to the NIH Clinical Center for 2-3 nights for melatonin treatment.
They take a single dose of melatonin or placebo tablet at bedtime. During the daytime,
EEG electrodes are placed to track eye movements. Between 7 PM and 7 AM serial blood
samples are collected to measure melatonin levels. A parent rates the child s behavior
and mood as described for the bright light study.
- Children may receive either or both of the bright light and melatonin treatments.
Part 2 Outpatient Trial
Children participate in a combined bright light with melatonin trial at home. They undergo
the same procedures outlined in the pre-trial at-home phase of Part 1 (actiwatch, behavior
assessments, body temperature measurements, saliva samples) over an 11-week period. If saliva
samples cannot be collected for melatonin testing, 24-hour urine samples may be collected
instead.
Status | Completed |
Enrollment | 23 |
Est. completion date | May 22, 2018 |
Est. primary completion date | May 22, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 45 Years |
Eligibility |
- INCLUSION CRITERIA: SMS subjects enrolled in protocol 01-HG-0109 will be invited to participate in this study. Protocol 01-HG-0109 has approximately 90 SMS subjects. SMS inpatient admissions for the dTR-MT trial will be deferred until the BL study completes 10 SMS subjects who demonstrate expected SMS inverted diurnal MT profiles at baseline (T0). SMS Subjects (N=12-15 per each treatment goal; 60 total enrollment): - Male and female, childhood (average 5-16 years old; under age 5 years on case-by-case basis), all ethnicities with confirmed diagnosis of SMS (del 17p11.2). In some cases, molecular cytogenetic FISH screening (RAI1 FISH probe) may be required to confirm the SMS diagnosis prior to enrollment. - Prepubertal (less than or equal to Tanner stage II). - No history of seizures - Priority will be given to subjects who are medication free and/or willing to discontinue sleep/behavioral medications during the study trial. We anticipate significant interest from families whose children are currently enrolled in the 01-HG-0109 protocol. We will also consider drug-free new referrals (self-referrals and/or via health care providers) eligible for enrollment. - Documented sleep disturbance (by sleep log diary and/or actigraphy). Unaffected Healthy Control Subjects (N=15). The pharmacokinetics of melatonin release by the dTR tablet will be evaluated in unaffected healthy control subjects prior to use in the inpatient SMS trial. - Males and females of any ethnicity and between the ages 18-45 years. - Regular (11PM - 7AM) sleep schedule for at least 1 week prior to study. - Non-smokers, who have no history of seizures. - Willing to discontinue coffee consumption for a period of 1-2 weeks prior to trial. - BMI within normal limits (10-90 percentile). - Unaffected with SMS. EXCLUSION CRITERIA: SMS Subjects: - Inability to obtain informed consent. - Failure to confirm clinical diagnosis of SMS by standard molecular cytogenetic (FISH) methods and/or DNA-based mutation analysis of RAI1 gene. - Retinal diseases: macular degeneration, retinitis pigmentosa, diabetes, cataracts. - Skin disease: Lupus (lupus erythematosis), history of skin cancer, history of adverse reaction(s) to sun (rash, reddening). - Medications that are photosensitizing: Phenothiazines (Thorazine, Stelazine), Imipramine (AD), Porphyrins (antitumor), Chloroquine (antimalarial), Hydrocholorthiazine (antihypertensive, diuretic), Lithium (mood stabilizer) and/or antibiotics (Tetracycline). - SMS subjects with extensive medication use may be excluded, depending on medications used and whether or not discontinuing medications for the trial presents a significant health risk. These include medications that might affect daytime vigilance (e.g., some seratonin antagonists such as Trazadone, SSRIs) and/or MAOIs, and/or antipsychotics (Risperidone), and/or some SSRIs (e.g., fluvoxamine) that affect the metabolism of melatonin and/or are strong CYP1A2 inhibitors. Healthy Adult Controls: - Individuals who have been diagnosed with a sleep disorder (e.g, restless legs, sleep apnea) known to impact sleep may be excluded at the discretion of the PI. - Not willing to discontinue caffeine consumption (chocolate, coffee, tea) during study period. - Persons with extensive medication use may be excluded, depending on medications used and whether or not discontinuing medications for the trial presents a significant health risk. These include medications that might affect daytime vigilance (e.g., some seratonin antagonists such as Trazadone, SSRIs) and/or MAOIs, and/or antipsychotics (Risperidone), and/or some SSRIs (e.g., fluvoxamine) that affect the metabolism of melatonin and/or are strong CYP1A2 inhibitors. - Employed on a shift work schedule. - Transmeridian travel within the last 2 weeks. - Currently using melatonin. - Women currently taking oral contraceptives (BCPs) - Pregnant women and/or nursing mothers |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) |
United States,
Bi W, Saifi GM, Shaw CJ, Walz K, Fonseca P, Wilson M, Potocki L, Lupski JR. Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. Hum Genet. 2004 Nov;115(6):515-24. Epub 2004 Sep 30. — View Citation
De Leersnyder H, De Blois MC, Claustrat B, Romana S, Albrecht U, Von Kleist-Retzow JC, Delobel B, Viot G, Lyonnet S, Vekemans M, Munnich A. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J Pediatr. 2001 Jul;139(1):111-6. — View Citation
Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH. Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet. 2003 Apr;33(4):466-8. Epub 2003 Mar 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in level of melatonin (pg/ml) from baseline | |||
Secondary | Improved sleep parameters (actigraphy). Increased daytime vigilance. Decreased maladaptive behaviors. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Recruiting |
NCT05991453 -
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
|
N/A | |
Withdrawn |
NCT05096130 -
Lifestyle Medicine Strategies for Combating Sleepiness and Fatigue in Professional Drivers
|
N/A | |
Completed |
NCT01327040 -
Light Sensitization Study
|
N/A | |
Completed |
NCT00593736 -
Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome
|
Phase 2 | |
Recruiting |
NCT00387179 -
Effectiveness of Combining Light and Non-Light Treatments for Jet Lag and Sleep Disorders
|
N/A | |
Recruiting |
NCT04900675 -
Bright Light Intervention to Reduce Students' Stress
|
N/A | |
Completed |
NCT01881854 -
Sleep Wake and Melatonin Pattern in Craniopharyngioma
|
N/A | |
Completed |
NCT00246051 -
Comprehensive Police Fatigue Management Program
|
N/A | |
Recruiting |
NCT04690504 -
Validation of Circadian Biomarkers in Patients With Sleep Disorders
|
||
Completed |
NCT03363529 -
ROOM-LIGHT: Dynamic LED-light as Treatment for Depressed Patients in Inpatient Wards
|
N/A | |
Recruiting |
NCT05701969 -
Effect of Melatonin on Sleep Patterns of Resident Trainees During Night Float Shift
|
Early Phase 1 | |
Completed |
NCT00723580 -
Actigraphic Analysis of Treatment Response
|
N/A | |
Completed |
NCT00207285 -
Sleep Disorders Management, Health and Safety in Police
|
N/A | |
Not yet recruiting |
NCT06336525 -
Adult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities.
|
||
Recruiting |
NCT05618405 -
Changes in Circadian Rhythm After Anaesthesia in Children
|
||
Completed |
NCT05684523 -
Feasibility Study on the Use of Redormin®500 on Day-time Cognition
|
Phase 4 | |
Recruiting |
NCT05247125 -
The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)
|
Phase 4 | |
Completed |
NCT04219566 -
Vestibular Nerve Stimulation to Improve Sleep
|
N/A | |
Not yet recruiting |
NCT06181110 -
Sleep-Wake Patterns on Illness Trajectories and Treatment Response in MDD
|
N/A |